Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester
The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HANNSRISTIAN MAHLER ULRIKE MARTINI-MARR CHRISTIANE BACHMANN ROBERT MUELLER UDO HAAS |
| description | The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ZA200401161B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ZA200401161B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ZA200401161B3</originalsourceid><addsrcrecordid>eNqNjDEKwkAQAK-xEPUP6wOERMVeg2JhKQg2YXPZ6MLl9rzbQO73pvABVtPMzNw8bvwZuIVOYj84VBYPVvoQObF_QUU6jNxjA-hbQAjisoyZ9J0deYIksWFFDx2qZkA7rSgpxaWZdegSrX5cmPXlfK-uGwpSUwpop1zr53FbFPuiLA_lafeP8wXW7Tq7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester</title><source>esp@cenet</source><creator>HANNSRISTIAN MAHLER ; ULRIKE MARTINI-MARR ; CHRISTIANE BACHMANN ; ROBERT MUELLER ; UDO HAAS</creator><creatorcontrib>HANNSRISTIAN MAHLER ; ULRIKE MARTINI-MARR ; CHRISTIANE BACHMANN ; ROBERT MUELLER ; UDO HAAS</creatorcontrib><description>The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.</description><edition>7</edition><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041022&DB=EPODOC&CC=ZA&NR=200401161B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041022&DB=EPODOC&CC=ZA&NR=200401161B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HANNSRISTIAN MAHLER</creatorcontrib><creatorcontrib>ULRIKE MARTINI-MARR</creatorcontrib><creatorcontrib>CHRISTIANE BACHMANN</creatorcontrib><creatorcontrib>ROBERT MUELLER</creatorcontrib><creatorcontrib>UDO HAAS</creatorcontrib><title>Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester</title><description>The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjDEKwkAQAK-xEPUP6wOERMVeg2JhKQg2YXPZ6MLl9rzbQO73pvABVtPMzNw8bvwZuIVOYj84VBYPVvoQObF_QUU6jNxjA-hbQAjisoyZ9J0deYIksWFFDx2qZkA7rSgpxaWZdegSrX5cmPXlfK-uGwpSUwpop1zr53FbFPuiLA_lafeP8wXW7Tq7</recordid><startdate>20041022</startdate><enddate>20041022</enddate><creator>HANNSRISTIAN MAHLER</creator><creator>ULRIKE MARTINI-MARR</creator><creator>CHRISTIANE BACHMANN</creator><creator>ROBERT MUELLER</creator><creator>UDO HAAS</creator><scope>EVB</scope></search><sort><creationdate>20041022</creationdate><title>Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester</title><author>HANNSRISTIAN MAHLER ; ULRIKE MARTINI-MARR ; CHRISTIANE BACHMANN ; ROBERT MUELLER ; UDO HAAS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ZA200401161B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2004</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HANNSRISTIAN MAHLER</creatorcontrib><creatorcontrib>ULRIKE MARTINI-MARR</creatorcontrib><creatorcontrib>CHRISTIANE BACHMANN</creatorcontrib><creatorcontrib>ROBERT MUELLER</creatorcontrib><creatorcontrib>UDO HAAS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HANNSRISTIAN MAHLER</au><au>ULRIKE MARTINI-MARR</au><au>CHRISTIANE BACHMANN</au><au>ROBERT MUELLER</au><au>UDO HAAS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester</title><date>2004-10-22</date><risdate>2004</risdate><abstract>The invention relates to a stable liquid pharmaceutical formulation comprising Cetuximab(R), a chimeric monoclonal antibody against the receptor of endothelial growth factor (EGF receptor). The formulation has increased storage stability and can be used parenterally for the treatment of tumours.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_ZA200401161B |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Liquid formulation comprising Cetuximab and a polyoxyethylene sorbitan fatty acid ester |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T14%3A41%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HANNSRISTIAN%20MAHLER&rft.date=2004-10-22&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EZA200401161B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |